Home > Research > Publications & Outputs > Can a medical need clause help manage the growi...

Research

Electronic data

  • Main document_anonymous_REVISED DRAFT(A)

    Rights statement: http://journals.cambridge.org/action/displayJournal?jid=HEP The final, definitive version of this article has been published in the Journal, Health Economics, Policy and Law, 11 (2), pp 179-192 2016, © 2016 Cambridge University Press.

    Accepted author manuscript, 108 KB, PDF document

Links

Text available via DOI:

View graph of relations

Can a medical need clause help manage the growing costs of prescription drugs in the EU?

Research output: Contribution to Journal/Magazine › Journal article › peer-review

Published

Standard

Can a medical need clause help manage the growing costs of prescription drugs in the EU? / Brooks, Eleanor; Geyer, Robert.
In: Health Economics, Policy and Law, Vol. 11, No. 2, 04.2016, p. 179-192.

Research output: Contribution to Journal/Magazine › Journal article › peer-review

Harvard

Brooks, E & Geyer, R 2016, 'Can a medical need clause help manage the growing costs of prescription drugs in the EU?', Health Economics, Policy and Law, vol. 11, no. 2, pp. 179-192. https://doi.org/10.1017/S1744133115000389

APA

Brooks, E., & Geyer, R. (2016). Can a medical need clause help manage the growing costs of prescription drugs in the EU? Health Economics, Policy and Law, 11(2), 179-192. https://doi.org/10.1017/S1744133115000389

Vancouver

Brooks E, Geyer R. Can a medical need clause help manage the growing costs of prescription drugs in the EU? Health Economics, Policy and Law. 2016 Apr;11(2):179-192. Epub 2015 Sept 3. doi: 10.1017/S1744133115000389

Author

Brooks, Eleanor ; Geyer, Robert. / Can a medical need clause help manage the growing costs of prescription drugs in the EU?. In: Health Economics, Policy and Law. 2016 ; Vol. 11, No. 2. pp. 179-192.

Bibtex

@article{74ef0ea95c724ae78ade715acdef5f96,
title = "Can a medical need clause help manage the growing costs of prescription drugs in the EU?",
abstract = "Innovation in the development of new drugs has to balance the needs of health actors and administrators, the pharmaceutical industry and patients. Differing perspectives on what constitutes an innovation, where research and development should be directed and how new drugs should be evaluated and priced cause ongoing tensions within the regulatory framework. In the current climate, where Europe{\textquoteright}s health systems face rising demand for health services and increasingly restricted resources, the efficiency of pharmaceutical regulation and drug development is under even greater scrutiny. How can regulation foster innovation and industry growth while also serving the public health needs of society, and what is the EU{\textquoteright}s role in pursuing this objective? Drawing on a provision which formerly existed in Norwegian pharmaceutical legislation, this article explores the potential of a medical need clause (MNC) in addressing these issues. In restricting market authorisations to those drugs that offer an added therapeutic value, might a MNC foster innovation and spending efficiency in Europe{\textquoteright}s health systems?",
author = "Eleanor Brooks and Robert Geyer",
note = "http://journals.cambridge.org/action/displayJournal?jid=HEP The final, definitive version of this article has been published in the Journal, Health Economics, Policy and Law, 11 (2), pp 179-192 2016, {\textcopyright} 2016 Cambridge University Press.",
year = "2016",
month = apr,
doi = "10.1017/S1744133115000389",
language = "English",
volume = "11",
pages = "179--192",
journal = "Health Economics, Policy and Law",
issn = "1744-1331",
publisher = "Cambridge University Press",
number = "2",

}

RIS

TY - JOUR

T1 - Can a medical need clause help manage the growing costs of prescription drugs in the EU?

AU - Brooks, Eleanor

AU - Geyer, Robert

N1 - http://journals.cambridge.org/action/displayJournal?jid=HEP The final, definitive version of this article has been published in the Journal, Health Economics, Policy and Law, 11 (2), pp 179-192 2016, © 2016 Cambridge University Press.

PY - 2016/4

Y1 - 2016/4

N2 - Innovation in the development of new drugs has to balance the needs of health actors and administrators, the pharmaceutical industry and patients. Differing perspectives on what constitutes an innovation, where research and development should be directed and how new drugs should be evaluated and priced cause ongoing tensions within the regulatory framework. In the current climate, where Europe’s health systems face rising demand for health services and increasingly restricted resources, the efficiency of pharmaceutical regulation and drug development is under even greater scrutiny. How can regulation foster innovation and industry growth while also serving the public health needs of society, and what is the EU’s role in pursuing this objective? Drawing on a provision which formerly existed in Norwegian pharmaceutical legislation, this article explores the potential of a medical need clause (MNC) in addressing these issues. In restricting market authorisations to those drugs that offer an added therapeutic value, might a MNC foster innovation and spending efficiency in Europe’s health systems?

AB - Innovation in the development of new drugs has to balance the needs of health actors and administrators, the pharmaceutical industry and patients. Differing perspectives on what constitutes an innovation, where research and development should be directed and how new drugs should be evaluated and priced cause ongoing tensions within the regulatory framework. In the current climate, where Europe’s health systems face rising demand for health services and increasingly restricted resources, the efficiency of pharmaceutical regulation and drug development is under even greater scrutiny. How can regulation foster innovation and industry growth while also serving the public health needs of society, and what is the EU’s role in pursuing this objective? Drawing on a provision which formerly existed in Norwegian pharmaceutical legislation, this article explores the potential of a medical need clause (MNC) in addressing these issues. In restricting market authorisations to those drugs that offer an added therapeutic value, might a MNC foster innovation and spending efficiency in Europe’s health systems?

U2 - 10.1017/S1744133115000389

DO - 10.1017/S1744133115000389

M3 - Journal article

VL - 11

SP - 179

EP - 192

JO - Health Economics, Policy and Law

JF - Health Economics, Policy and Law

SN - 1744-1331

IS - 2

ER -